Annual Report 2023

NOTESTOTHE CONSOLIDATED FINANCIAL STATEMENTS For the year ended 31 December 2023 82 The United Laboratories International Holdings Limited Annual Report 2023 5. REVENUE AND SEGMENT INFORMATION (Continued) (i) Disaggregation of revenue from contracts with customers For the year ended 31 December 2023 Intermediate Bulk Finished Segments products medicine products Total Elimination Consolidated RMB’000 RMB’000 RMB’000 RMB’000 RMB’000 RMB’000 Types of products – 6-APA 1,344,293 – – 1,344,293 – 1,344,293 – Antibiotics products – 6,393,056 3,532,798 9,925,854 – 9,925,854 – Insulin Products – – 1,063,813 1,063,813 – 1,063,813 – Others 972,585 6,124 427,210 1,405,919 – 1,405,919 Revenue from contracts with customers 2,316,878 6,399,180 5,023,821 13,739,879 – 13,739,879 Inter-segment sales 3,436,223 993,005 – 4,429,228 (4,429,228) – Segment revenue 5,753,101 7,392,185 5,023,821 18,169,107 (4,429,228) 13,739,879